P

harmacy benefit managers are finding themselves in the spotlight more than they used to — and their top lobbyist doesn’t mind.

PBMs and the lobbyists who advocate for them, unsurprisingly, see things differently from Congressman Doug Collins of Georgia, a Republican who last week excoriated PBMs in an interview with STAT. STAT also spoke with Mark Merritt, the CEO of the Pharmaceutical Care Management Organization, about how PBMs view their work.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy